Valerio Therapeutics (FR:ALVIO)
:ALVIO
Want to see FR:ALVIO full AI Analyst Report?
ALVIO Stock Chart & Stats
€0.06
<€0.01(1.53%)
At close: 4:00 PM EST
€0.06
<€0.01(1.53%)
Day’s Range― - ―
52-Week Range€0.04 - €0.31
Previous CloseN/A
Volume8.86K
Average Volume (3M)1.36M
Market Cap
€84.76M
Enterprise Value€66.00M
Total Cash (Recent Filing)€1.05M
Total Debt (Recent Filing)€7.61M
Price to Earnings (P/E)―
Beta-0.91
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding499,448,300
10 Day Avg. Volume527,429
30 Day Avg. Volume1,357,798
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)10.27
Price to Sales (P/S)8.28
P/FCF Ratio40.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Rebound & Strong Gross MarginsA ~40.6% revenue rebound in 2025 combined with sustained ~67–71% gross margins signals improving commercial traction or milestone/licensing progress and an underlying scalable cost structure. For a clinical biotech this supports reinvestment in R&D and improves the odds of reaching durable profitability if growth persists.
Operating And Free Cash Flow Turned PositivePositive operating and free cash flow in 2025 marks a structural shift after years of burn, improving runway and reducing immediate financing pressure. Sustainable OCF/FCF would allow the company to fund clinical programs more from operations, lowering dilution risk and enhancing strategic optionality for partnerships or milestone financing.
Focused Clinical-stage Oncology R&D ModelA concentrated R&D focus on small-molecule DNA/RNA oncology therapeutics creates a clear strategic identity and high barriers to entry. This specialization can yield deep technical expertise, attractive licensing or partnership opportunities, and meaningful upside if lead programs advance, aligning with durable industry demand for novel cancer therapies.
Bears Say
Elevated Leverage And Balance-sheet VolatilityMaterially higher leverage and swings in equity reflect balance-sheet fragility. High debt-to-equity (~3.7x) constrains financial flexibility, increases refinancing and interest risk, and limits capacity to absorb clinical setbacks. This elevates funding risk for capital-intensive trials over the medium term.
Ongoing Net LossesDespite operational gains, the company remains loss-making (≈-4.9M in 2025). Persistent negative net income implies continued reliance on external funding to scale, which can dilute shareholders and create execution risk if capital markets or partner funding tighten before sustainable profitability is achieved.
Volatile Cash Generation And Asset DeclineCash-generation improvements in 2025 appear uneven and historically volatile, while total assets have declined. This uneven track record raises sustainability concerns: a renewed R&D spend or trial cost increase could revert cash flow to burn, undermining the recent positive inflection and forcing costly financing.
ALVIO FAQ
What was Valerio Therapeutics’s price range in the past 12 months?
Valerio Therapeutics lowest stock price was €0.04 and its highest was €0.31 in the past 12 months.
What is Valerio Therapeutics’s market cap?
Valerio Therapeutics’s market cap is €84.76M.
When is Valerio Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Valerio Therapeutics’s earnings last quarter?
Currently, no data Available
Is Valerio Therapeutics overvalued?
According to Wall Street analysts Valerio Therapeutics’s price is currently Overvalued.
Does Valerio Therapeutics pay dividends?
Valerio Therapeutics does not currently pay dividends.
What is Valerio Therapeutics’s EPS estimate?
Valerio Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valerio Therapeutics have?
Valerio Therapeutics has 499,448,300 shares outstanding.
What happened to Valerio Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Valerio Therapeutics?
Currently, no hedge funds are holding shares in FR:ALVIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valerio Therapeutics
Valerio Therapeutics Société anonyme, a clinical-stage biotechnology company, designs and develops oncology drugs for tumor DNA repair functions worldwide. The company offers Beleodaq for the treatment of peripheral T-cell lymphoma. It also develops AsiDNA, which is in Phase 1 clinical trial for the treatment of metastatic melanoma; OX401, which is in preclinical stage for treating DNA damage response and immuno-oncology; and platON, a decoy oligonucleotide platform. It has a license agreement with Acrotech Biopharma LLC; and clinical research agreement with Gustave Roussy to conduct clinical trial of AsiDNA for the treatment of relapsed ovarian cancer. The company was formerly known as Onxeo SA and changed its name to Valerio Therapeutics Société anonyme in June 2023. Valerio Therapeutics Société anonyme was incorporated in 1997 and is headquartered in Paris, France.
Technical Analysis
Innate Pharma SA
―
Transgene
―
OSE Immunotherapeutics SA
―
GenSight Biologics SA
―
Cellectis SA
―